These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23772696)

  • 41. Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.
    Kearton S; Wills K; Bunting M; Blomfield P; James PA; Burke J
    Fam Cancer; 2018 Jul; 17(3):333-344. PubMed ID: 29039136
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
    Roukos DH; Briasoulis E
    Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan.
    Arai M; Yokoyama S; Watanabe C; Yoshida R; Kita M; Okawa M; Sakurai A; Sekine M; Yotsumoto J; Nomura H; Akama Y; Inuzuka M; Nomizu T; Enomoto T; Nakamura S
    J Hum Genet; 2018 Apr; 63(4):447-457. PubMed ID: 29176636
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
    Scheuer L; Kauff N; Robson M; Kelly B; Barakat R; Satagopan J; Ellis N; Hensley M; Boyd J; Borgen P; Norton L; Offit K
    J Clin Oncol; 2002 Mar; 20(5):1260-8. PubMed ID: 11870168
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
    Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
    Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hereditary breast cancer: an update on risk assessment and genetic testing in 2015.
    Stuckey AR; Onstad MA
    Am J Obstet Gynecol; 2015 Aug; 213(2):161-5. PubMed ID: 25747548
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.
    Morgan D; Sylvester H; Lucas FL; Miesfeldt S
    Fam Cancer; 2009; 8(4):277-87. PubMed ID: 19347608
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence.
    Shah P; Rosen M; Stopfer J; Siegfried J; Kaltman R; Mason B; Armstrong K; Nathanson KL; Schnall M; Domchek SM
    Breast Cancer Res Treat; 2009 Dec; 118(3):539-46. PubMed ID: 19609668
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Genetical aspects of surgical treatment in patients with hereditary breast cancer].
    Bit-Sava EM
    Vestn Khir Im I I Grek; 2014; 173(5):27-30. PubMed ID: 25823331
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Breast MRI fibroglandular volume and parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before and immediately after risk-reducing salpingo-oophorectomy.
    DeLeo MJ; Domchek SM; Kontos D; Conant E; Chen J; Weinstein S
    AJR Am J Roentgenol; 2015 Mar; 204(3):669-73. PubMed ID: 25714301
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
    Hartmann LC; Sellers TA; Schaid DJ; Frank TS; Soderberg CL; Sitta DL; Frost MH; Grant CS; Donohue JH; Woods JE; McDonnell SK; Vockley CW; Deffenbaugh A; Couch FJ; Jenkins RB
    J Natl Cancer Inst; 2001 Nov; 93(21):1633-7. PubMed ID: 11698567
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening.
    Krajc M; Zadnik V; Novaković S; Stegel V; Teugels E; Bešič N; Hočevar M; Vakselj A; De Grève J; Zgajnar J
    Clin Genet; 2014 Jan; 85(1):59-63. PubMed ID: 23397983
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Retrospective Analysis of the Relationship Between the Result of BRCA1/2 Genetic Testing and Surgical Method Selection in Japan.
    Inuzuka M; Watanabe C; Yokoyama S; Kuwayama T; Akashi-Tanaka S; Arai M; Nakamura S;
    Clin Breast Cancer; 2021 Feb; 21(1):e48-e52. PubMed ID: 32928640
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification and management of familial breast cancer in Austria.
    Singer CF; Tan YY; Rappaport C
    Horm Mol Biol Clin Investig; 2017 Nov; 32(2):. PubMed ID: 29190211
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries].
    Menkiszak J; Chudecka-Głaz A; Gronwald J; Bedner R; Cymbaluk-Płoska A; Wezowska M; Zielińska D; Rzepka-Górska I
    Ginekol Pol; 2013 Sep; 84(9):758-64. PubMed ID: 24191513
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.
    Cragun D; Weidner A; Lewis C; Bonner D; Kim J; Vadaparampil ST; Pal T
    Cancer; 2017 Jul; 123(13):2497-2505. PubMed ID: 28182268
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users.
    Jacobs C; Pichert G; Harris J; Tucker K; Michie S
    Psychooncology; 2017 Nov; 26(11):1818-1824. PubMed ID: 28101941
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Health Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population?
    Randall TC; Armstrong K
    Curr Treat Options Oncol; 2016 Aug; 17(8):39. PubMed ID: 27315065
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hereditary breast and ovarian cancer.
    Barks P; Goldgar C
    JAAPA; 2012 Mar; 25(3):63-5. PubMed ID: 22514962
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.